Abstract:ABSTRACT BACKGROUND/PURPOSE: There is currently no standard effective treatment for patients with relapsed/refractory primary central nervous system lymphoma (PCNSL). The prognosis is poor, so more studies are needed. Pemetrexed is similar to methotrexate in structure and can cross the blood-brain barrier. Compared with methotrexate, it has more targets and fewer side effects. Lenalidomide is a second generation immunomodulator with multiple functions, such as regulating immunity, anti-tumor and tumor microenvironment. A prospective observational study was conducted to explore the efficacy and safety of pemetrexed combined with lenalidomide in the treatment of relapsed/refractory primary central nervous system lymphoma. METHODS: This is a prospective observational study, we collected patients who had undergone whole brain radiotherapy and two or more chemotherapy regimens between January 2018 and December 2019 but still experienced disease progression or recurrence. each patient was treated with pemetrexed at a dose of 900mg/m2 and lenalidomide 25mg over 3 weeks as salvage chemotherapy, and one cycle consists of 4 weeks. Folic acid, vitamin B12 and dexamethasone were used to induce toxicities to pemetrexed given before chemotherapy. Oral aspirin was used to prevent thrombosis caused by lenalidomide. Adverse events were recorded in each patient during inpatients, outpatient or telephone follow-up. RESULTS: A total of 38 patients with recurrent/refractory PCNSL were enrolled in our study, including 26 males and 12 females with a median age of 57 (range from 33 to 73) years old. After treatment, the overall response rate was 68.4%(Table 1). The median progression free survival (PFS) time was 6 months and median overall survival (OS) time was 14 months (Figure1, Figure2). The adverse events mainly included fatigue, gastrointestinal reaction, myelosuppression, thrombocytopenia, fever and infection. After long-term or short-term chemotherapy, the patients had different degrees of myelosuppression symptoms presented as leukopenia (six cases in grade 1 and one case in grade 3), neutropenia (six cases in grade 1 and two cases in grade 3), anemia (6 cases in grade 1), thrombocytopenia (1 case in grade 2 and 3 cases in grade 3). Nausea and vomiting, as the common gastrointestinal reaction, appeared in two (grade 1) and one (grade 2) cases, respectively. One patient died of severe pneumonia infection. Three cases developed grade 1 cardiac disorder, including asymptomatic sinus bradycardia and asymptomatic ventricular premature beat, respectively. In addition, other reactions including fatigue (four cases in grade 1 and one case in grade 2), fever (four cases). All patients had no abnormal liver function, kidney function, constipation and leukoencephalopathy (Table 2). CONCLUSION: This study has been the first prospective clinical study of pemetrexed combined with lenalidomide in the treatment of patients with relapsed/refractory PCNSL in international. The results indicate that chemotherapy with pemetrexed combined with lenalidomide may be an effective therapy for the treatment of relapsed/refractory PCNSL with modest toxicity. KEYWORDS: Primary central nervous system lymphoma; Relapse/refractory; Pemetrexed combined with lenalidomide; Efficacy; Safety Disclosures No relevant conflicts of interest to declare.

Efficacy and Safety of Pemetrexed Combined with Lenalidomide in the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma

Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

Pemetrexed for Recurrent Primary Central Nervous System Lymphoma in the Elderly: Results of a Retrospective Study

Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.

1439P Brain Radiotherapy Combined with Camrelizumab and Platinum-Based Chemotherapy As First-Line Treatment for Advanced NSCLC with Brain Metastases: A Multicenter, Open-Label, Single-Arm, Phase II Study

Lenalidomide, Rituximab and Methotrexate（R2-MTX）in Newly Diagnosed Primary Central Nervous System Lymphoma

High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom

Pemetrexed Alone Regimen in Treatment of Advanced Chemo-Recurrent Non-Small Cell Lung Cancer

Pemetrexed and Platinum As First-Line Chemotherapy for Advanced Lung Adenocarcinoma:An Observation of Recent Therapeutic Effects and a Safety Profile

The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first‐line methotrexate treatment: A retrospective study

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Clinical Analysis of Chimeric Antigen Receptor T Cells Immunotherapy in Treatment of One Patient with Relapsed/refractory Primary Central Nervous System Lymphoma

Fotemustine-Based in Combination with Rituximab As First-Line Induction Chemotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma:a Prospective Phaseii Trial

Efficacy and Safety of Pemetrexed Maintenance Chemotherapy for Advanced Non-Small Cell Lung Cancer in a Real-World Setting

Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas

Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin Versus Temozolomide for the Treatment of Non-small Cell Lung Cancer with Brain Metastases.

Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China

Lenalidomide with R-IMED (rituximab, Ifosfamide, Methotrexate, Etoposide and Dexamethasone) in Refractory or Relapsed Non-Gcb Diffuse Large B-cell Lymphoma: A Phase II Clinical Trial.

A Phase II Study of the Efficacy and Safety of the Srmt (Sintilimab, Rituximab, Methotrexate, and Temozolomide) Regimen in Newly Diagnosed Primary Central Nervous System Lymphoma

Efficacy and Safety of Lenalidomide, Rituximab Combined with Second-Line Chemotherapy (R2-chemo) in Patients with Relapsed/Refractory Diffuse Large-B Cell Lymphoma